Douglas B. Johnson, M.D. Assistant Professor of Medicine Clinical Director, Melanoma Research Program Melanoma, clinical and translational studies Vanderbilt University Medical Center

Fatal Toxicities Rare With Checkpoint Inhibitors

MedicalResearch.com Interview with:

Douglas B. Johnson, M.D. Assistant Professor of Medicine Clinical Director, Melanoma Research Program Melanoma, clinical and translational studies Vanderbilt University Medical Center

Dr. Johnson

Douglas B. Johnson, M.D.
Assistant Professor of Medicine
Clinical Director, Melanoma Research Program
Melanoma, clinical and translational studies
Vanderbilt University Medical Center

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Immune checkpoint inhibitors produce long-lasting responses in patients with many different types of cancer. However, they may cause serious autoimmune-like side effects that may affect any organ. We used several large databases to determine how often these side effects were fatal, when they occurred, and which types of side effects were responsible.

We found that overall, fatal side effects were uncommon, ranging from 0.3 – 1.3%. However, they tended to occur early on treatment (on average within the first 6 weeks), and affected a variety of organs, including the heart, lungs, colon, liver, and brain. There was a dramatic increase in reporting of fatal toxicities since 2017, likely reflecting the increased use of immune checkpoint inhibitors. 

MedicalResearch.com: What should readers take away from your report?

Response: While fatal side effects are uncommon, recognizing immune checkpoint inhibitor toxicities is essential to protect patients. Early diagnosis and treatment with steroids are the most effective ways of managing these side effects.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Developing better preventions and treatments for the most serious side effects is an important next step. While steroids are very effective in most cases, there are a subset of toxicities that are challenging to manage and more effective treatments are needed.

Citation:

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors a systematic review and meta-analysis. [published online September 13, 2013]. JAMA Oncol. doi:10.1001/jamaoncol.2018.3923.

[wysija_form id=”3″]

[last-modified]

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Last Updated on September 13, 2018 by Marie Benz MD FAAD